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The added value of incorporating information from repeated blood pressure and cholesterol measurements to
predict cardiovascular disease (CVD) risk has not been rigorously assessed. We used data on 191,445 adults from
the Emerging Risk Factors Collaboration (38 cohorts from 17 countries with data encompassing 1962–2014) with
more than 1million measurements of systolic blood pressure, total cholesterol, and high-density lipoprotein choles-
terol. Over a median 12 years of follow-up, 21,170 CVD events occurred. Risk prediction models using cumulative
mean values of repeated measurements and summary measures from longitudinal modeling of the repeated mea-
surements were compared with models using measurements from a single time point. Risk discrimination (C-
index) and net reclassiﬁcation were calculated, and changes in C-indices were meta-analyzed across studies.
Compared with the single-time-point model, the cumulative means and longitudinal models increased the C-index
by 0.0040 (95% conﬁdence interval (CI): 0.0023, 0.0057) and 0.0023 (95% CI: 0.0005, 0.0042), respectively.
Reclassiﬁcation was also improved in bothmodels; compared with the single-time-point model, overall net reclassi-
ﬁcation improvements were 0.0369 (95% CI: 0.0303, 0.0436) for the cumulative-means model and 0.0177 (95%
CI: 0.0110, 0.0243) for the longitudinal model. In conclusion, incorporating repeated measurements of blood pres-
sure and cholesterol into CVD risk prediction models slightly improves risk prediction.
cardiovascular disease; longitudinal measurements; repeated measurements; risk factors; risk prediction
Abbreviations: CI, conﬁdence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; NRI, net reclassiﬁcation
improvement; SBP, systolic blood pressure; SD, standard deviation.
Editor’s note:An invited commentary on this article appears
on page 908.
Established risk factors for cardiovascular disease (CVD),
such as high systolic blood pressure (SBP) and elevated blood
cholesterol levels, are routinely measured in general practice to
predict CVD risk through the use of CVD risk scores (1, 2) and
are also targets of treatments designed to modify risk (3). How-
ever, existing CVD risk scores are based on assessment of risk
factors measured at only a single time point, and the added value
of incorporating information from repeated measurements of
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risk predictors for prediction of CVD risk has not been thor-
oughly evaluated.
Repeated measurements of risk factors provide valuable
information on an individual’s risk trajectory over time and his
or her within-person variability. The use of repeated measure-
ments of risk predictors in the prediction of CVD risk has been
mostly focused on correcting for regression dilution (4–6), using
the change between 2 measurements (7), examining the use of
updated measurements versus historical measurements (8, 9),
and investigating the predictive ability of SBP variability (10, 11).
However, there are modeling approaches available that allow
modeling of longitudinal changes estimated from all available
repeated measurements, including regression calibration appro-
aches (12) that estimate “usual” risk factor levels. Another ap-
proach is longitudinal modeling that offers the advantage of
being able to model intraindividual differences over time while
still accounting for the correlation in repeated measurements (13).
This approach was utilized in a population study to incorporate
information on blood pressure trajectories into CVD risk pre-
diction models (14) and in a recent simulation study that exam-
ined the potential of joint longitudinal and survival models for
modeling systolic and diastolic blood pressure trajectories (15).
We have previously compared alternative methods of including
repeated measurements of SBP in a CVD risk prediction model
using a single study, but found no beneﬁt of joint models over
simpler methods (16). However, to our knowledge, no previous
studies have quantiﬁed the improvement in predictive ability
that can be gained when repeated measurements of several
risk predictors are included in CVD risk prediction algorithms
as comparedwith the usual approach of using data from a single
time point.
We conducted a large-scale individual-participant-data meta-
analysis of 191,445 adults without a history of CVD at baseline
to investigate the utilization of repeatedmeasurements of contin-
uous conventional risk factors, including SBP, total cholesterol,
and high-density lipoprotein (HDL) cholesterol, in CVD risk
predictionmodels.We used 2methods of increasing complexity
to model repeated measurements: 1) cumulative mean values and
2) individual-speciﬁc intercepts and slopes from mixed-effects
linear regression models. Our aim was to quantify the change
in risk discrimination and stratiﬁcation of people according to
their predicted 5-year CVD risk when the information from
repeated measurements of risk predictors was added to
the assessment of single measurements of risk factor levels used
in standard risk scores.
METHODS
Study design
We used data from 38 prospective studies included in the
Emerging Risk Factors Collaboration (17), encompassing the
years 1962–2014. Studies were included in the current analysis
if they met all of the following criteria: 1) at least 10 CVD
deaths or vascular events (nonfatal myocardial infarction or
stroke) or both were recorded during follow-up; 2) there were
5 or more years of follow-up; and 3) at least 1% of participants
had repeated measurements of SBP, total cholesterol, and
HDL cholesterol. Of the studies that met the inclusion criteria,
participants were only included in the analysis if they did not
have a recorded baseline history of CVD (i.e., myocardial
infarction, angina, or stroke), were aged 40–79 years at baseline,
and had complete information on baseline age, sex, smoking sta-
tus, history of diabetes, SBP, and total and HDL cholesterol
levels (i.e., the “conventional risk factors” included in standard
clinical risk scores). Since the peoplewho had repeatedmeasure-
ments were not a random sample of the original cohort, we
aimed to minimize selection bias by including all participants
in the analysis regardless of whether they had postbaseline
repeated measurements of SBP, total cholesterol, and HDL
cholesterol.
A list of study investigators and contributors is given in
Web Appendix 1 (available at https://academic.oup.com/aje).
Details of the included studies, including information on acro-
nyms, study design, population source, and country, are provided
inWebAppendix 2. The studywas approved byCambridgeshire
Research Ethics Committee.
Statistical analysis
The outcome in our analysis was a ﬁrst CVD event, deﬁned
as nonfatal myocardial infarction or any stroke using well-
deﬁned study-speciﬁc criteria, or any fatal CVD. Participants
were followed up until their ﬁrst CVD event, their death, the
end of the study, or loss to follow-up, whichever came ﬁrst.
We censored individuals at the end of follow-up or if they died
from non-CVD causes. In registering fatal outcomes, the
majority of contributing studies used the International Classiﬁ-
cation of Diseases (Eighth–Tenth Revisions), coding to at least
3 digits, and ascertainment was based on death certiﬁcates,
with 31 of 38 studies also involving medical records, autopsy
ﬁndings, and other supplementary sources.
Study-speciﬁc regression dilution ratios (18) were estimated
for SBP, total cholesterol, and HDL cholesterol to summarize
the within-person variability in themeasurements over time.
Each study was randomly split into two 50% samples.
Derivation of the longitudinal models included all available
data from the ﬁrst sample and data from the second sample
censored at the prediction time (see schematic in Web Fig-
ure 1 (parts A and B)). Derivation of the Cox proportional
hazards models included all available data from the ﬁrst sam-
ple. Model validation was done using data from the second
sample.
CVD risk prediction models were derived using Cox
proportional hazards models, stratiﬁed by study and sex,
and adjusting for baseline levels of conventional risk fac-
tors (age, smoking status, and history of diabetes) to esti-
mate log hazard ratios. We compared 3 different models
for incorporating available measurements of SBP, total
cholesterol, and HDL cholesterol as predictors in the Cox
models:
1. Model 1 used baseline measurements of SBP, total cho-
lesterol, and HDL cholesterol.
2. Model 2 used cumulative mean values of SBP, total cho-
lesterol, and HDL cholesterol, estimated from all previ-
ous repeated measurements and included in the model as
time-varying covariates.
3. Model 3 used individual-speciﬁc random intercept and
slope terms estimated from univariate mixed-effects linear
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regression models of repeated measurements of SBP, total
cholesterol, andHDL cholesterol. Singlemixed-effectsmodels
using data from all studies were ﬁtted to the longitudinal data
separately for SBP, total cholesterol, andHDL cholesterol, and
results were adjusted for baseline levels of conventional risk
factors, treating study as a random effect.
For the purposes of putting our results into context, we also
generated a basic model including only age, sex, smoking sta-
tus, and history of diabetes as predictors, and we examined the
change in risk discrimination when single measurements of
SBP, total cholesterol, and HDL cholesterol were each added
separately to this model. The proportional hazards assumption
was tested using previously described methods (19).
Among individuals contributing data to the model valida-
tion, 5-year CVD risk predictions were made at the time of the
last repeat measurement taken prior to 5 years before the end of
follow-up. For studies of long duration (>20 years), this was
the time of the last repeat measurement taken prior to 15 years.
No future data from individuals contributing data to the valida-
tion was used in model derivation or risk prediction. The time
at which CVD risk prediction was estimated differed across in-
dividuals but was consistent across the 3models being compared.
In model 1, risk prediction was done using the last observation
carried forward—that is, the latest measurement of blood pressure
and cholesterol levels.
To quantify the change in risk prediction performance
between the models using repeated measurements (models 2
and 3) and the model using single measurements (model 1),
we compared discrimination (using the C-index, a measure
of how well the model discriminates between individuals
with and without CVD (20)) and risk reclassiﬁcation using the
validation data. The C-index and its changes were calculated
within each study separately before pooling of results using
meta-analysis weighted by the number of events occurring in
individuals contributing to the validation in each study (21).
Heterogeneity in C-indices between studies was quantiﬁed
using the I2 statistic (22). Univariate meta-regression analyses
were used to explore possible sources of heterogeneity in the
changes in C-indices, including mean age, mean number of re-
peats, and maximum follow-up time in each study. We con-
structed reclassiﬁcation tables using data from all studies
combined to examine the movement of participants among
predicted 5-year CVD risk categories (“low risk,” <2.5%;
“medium risk,” 2.5%–3.74%; “high risk,”≥3.75%). The 5-year
risk cutpoints were chosen by halving the current US 10-year
CVD treatment thresholds (23). Since treatment thresholds vary
between countries and over time, we also calculated a continu-
ous (“category-free”) net reclassiﬁcation improvement (NRI)
measure (24). Bootstrappingwas used to obtain 95% conﬁdence
intervals for the overall NRI and its components.
Four sensitivity analyses were undertaken. First, we exam-
ined whether the study results varied when ﬁtting separate sur-
vival models for each study and, for model 3, when study was
treated as a ﬁxed effect in the longitudinal models. For model 3,
we also examined the effects of ﬁtting mixed-effects longitudi-
nal models separately for each study. Second, we examined
whether the change in C-index was sensitive to the number of
repeats available by restricting the data to participants with 2 or
more postbaseline repeated measurements of SBP. Third, we
investigated whether the change in C-index varied between
younger (age<70 years) and older (age≥70 years) participants.
Finally, we restricted the analyses to studies with 10 years of
follow-up and estimated 10-year CVD risk to examine the
impact of modeling repeated measurements on longer-term risk
prediction.
Analyses were performed using Stata statistical software,
version 13.1 (StataCorp LP, College Station, Texas), and
95% conﬁdence intervals were generated for all effect sizes.
RESULTS
Among the 191,445 participants, themean age at baseline was
55 years (standard deviation, 9.5; range, 40–79); 106,773 partici-
pants (56%)weremen, and 62,519 (33%)were smokers. Table 1
Table 1. Baseline Characteristics of Participants in the Derivation and Validation Data Sets and Distribution of RepeatedMeasurements in a
Study of Cardiovascular Disease Risk Prediction, Emerging Risk Factors Collaboration, 1962–2014
Characteristic
Baseline No. of RepeatedMeasurements in the Derivation Data
Derivation Data (n= 191,445) Validation Data (n= 95,731) 0 1 2–4 ≥5
No. of
Persons % Mean (SD)
No. of
Persons % Mean (SD)
No. of
Persons %
No. of
Persons %
No. of
Persons %
No. of
Persons %
Age, years 55.2 (9.5) 55.3 (9.5)
Male sex 106,773 56 53,631 56
Current smoker 62,519 33 31,488 33
History of
diabetes
16,311 9 8,218 9
SBP,mmHg 133.9 (20.9) 133.8 (20.9) 79,293 43 36,969 20 50,872 28 16,987 9
Total cholesterol,
mmol/L
5.9 (1.2) 5.9 (1.2) 79,304 43 50,933 28 44,723 24 9,161 5
HDL cholesterol,
mmol/L
1.3 (0.4) 1.3 (0.4) 90,816 49 49,566 27 37,022 20 6,717 4
Abbreviations: HDL, high-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.
Am J Epidemiol. 2017;186(8):899–907
Repeated Risk Factor Measurements in CVDRisk Prediction 901
shows the baseline characteristics of participants contributing
data to the derivation and validation components, as well as the
distribution of repeated measurements in the derivation data set.
During a total of 2.5 million person-years of follow-up among all
participants (median, 12.2 years; interquartile range, 7.0–17.7),
there were 21,170CVD events.
Overall, there were 340,280 postbaseline measurements for
SBP (an average of 1.8 per person), 266,361 for total cholesterol
(an average of 1.4 per person), and 222,610 for HDL cholesterol
(an average of 1.2 per person). Compared with those with no
repeated measurements, participants with at least 1 postbaseline
measurement were slightly older (mean age = 56.5 years vs.
54.7 years), more likely to be male (59% vs. 51%), less likely to
be current smokers (29% vs. 38%), and more likely to have dia-
betes (10% vs. 6%); P values from χ2 tests were less than 0.001
for all comparisons. In the data used to derive the longitudinal
models, 60% of participants had at least 1 postbaseline repeated
measurement, and there were on average 2.3 years, 2.6 years,
and 2.7 years between repeated measurements for SBP, total
cholesterol, and HDL cholesterol, respectively. In the data used
to estimate CVD risk prediction, there were on average 0.5
years, 0.5 years, and 0.8 years between the time of last observa-
tion and prediction time for SBP, total cholesterol, and HDL
cholesterol, respectively.
Summary statistics, the distributions of repeated measure-
ments, baseline characteristics, and scatterplots of repeated
measurements and numbers of CVD events occurring over
time among all participants are given in Web Tables 1–3 and
Web Figure 2 for each included study. The regression dilu-
tion ratio for SBP was 0.52 (95% conﬁdence interval (CI):
0.50, 0.55), indicating greater within-person variability than
for total cholesterol (regression dilution ratio = 0.60, 95%
CI: 0.58, 0.62) and HDL cholesterol (regression dilution
ratio = 0.69, 95% CI: 0.67, 0.70) (Web Figure 3). Results
from the longitudinal models of SBP, total cholesterol, and
HDL cholesterol are shown inWeb Table 4.
Across all risk prediction models, hazard ratios were statis-
tically signiﬁcant for all conventional risk factors (Table 2).
The hazard ratios for the intercept of SBP and total cholesterol
were slightly greater in models 2 and 3 than in model 1. The
slopes of total cholesterol and HDL cholesterol, but not SBP,
were associated with CVD risk in model 3.
Of the 95,731 participants contributing data to the valida-
tion data set, 5,004 had a CVD event during the 5-year period
after the time at which the CVD risk prediction was esti-
mated. The distributions of absolute CVD risk predictions
were similar across the 3 models (Web Figure 4).
Changes in CVD risk discrimination
The basic risk prediction model that included only age, sex,
smoking status, and history of diabetes had an overall C-index
of 0.6333 (95% CI: 0.6257, 0.6409). Adding single measure-
ments of SBP, total cholesterol, and HDL cholesterol separately
improved the C-index by 0.0203 (95% CI: 0.0167, 0.0239),
0.0067 (95% CI: 0.0044, 0.0089), and 0.0104 (95% CI: 0.0086,
Table 2. Hazard Ratiosa for Cardiovascular Disease in the Derivation Data for EachModel in a Study of
Cardiovascular Disease Risk Prediction, Emerging Risk Factors Collaboration, 1962–2014
Risk Factor
Model 1b Model 2c Model 3d
HR 95%CI HR 95%CI HR 95%CI
Baseline age, years 1.08 1.08, 1.08 1.08 1.08, 1.08 1.09 1.09, 1.10
Current smoking (yes vs. no) 1.73 1.66, 1.80 1.73 1.66, 1.81 1.74 1.67, 1.81
History of diabetes (yes vs. no) 1.89 1.66, 1.80 1.90 1.78, 2.02 2.10 1.98, 2.24
SBP
Intercepte 1.35 1.33, 1.38 1.40 1.37, 1.43 1.42 1.40, 1.45
Slopef 1.02 0.98, 1.07
Total cholesterol
Intercept 1.19 1.16, 1.21 1.21 1.19, 1.24 1.26 1.23, 1.29
Slope 1.09 1.04, 1.15
HDL cholesterol
Intercept 0.85 0.83, 0.87 0.84 0.82, 0.86 0.85 0.83, 0.88
Slope 0.94 0.88, 1.00
Abbreviations: CI, conﬁdence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard
ratio; SBP, systolic blood pressure; SD, standard deviation.
a HRs fromCVD risk models stratiﬁed by study and sex. Where appropriate, results were adjusted for baseline age,
smoking status, history of diabetes, SBP, total cholesterol, and HDL cholesterol.
b Model 1 used baselinemeasures of SBP, total cholesterol, and HDL cholesterol.
c Model 2 used cumulativemean values of SBP, total cholesterol, and HDL cholesterol.
d Model 3 used individual-level random intercepts and slopes for SBP, total cholesterol, and HDL cholesterol.
e HRs for SBP, total cholesterol, and HDL cholesterol are given per SD increase. For model 3, these are the SD in-
creases in the random intercept.
f HRs for slopes are given per SD increase (using the SD of the random-effects slopes).
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0.0121), respectively (Figure 1). The addition of single measure-
ments of these combined risk factors (model 1) to the basic risk
prediction model improved risk discrimination by 0.0355 (95%
CI: 0.0313, 0.0396). In comparisonwithmodel 1, using cumula-
tive mean values and summary statistics from longitudinal mod-
els improved the overall C-index by 0.0040 (95% CI: 0.0023,
0.0057) and 0.0023 (95%CI: 0.0005, 0.0042), respectively. The
change in C-index in model 3 was statistically signiﬁcantly
smaller than that inmodel 2 (P< 0.001). Therewas considerable
between-study heterogeneity in C-indices (I2 = 99% for all
models (P < 0.001); Web Figure 5) but less for the changes in
C-indices (for model 2 vs. model 1, I2 = 67% (P < 0.001), and
for model 3 vs. model 1, I2 = 74% (P < 0.001); Web Figure 6).
There was no evidence that heterogeneity was explained by
mean age, mean number of postbaseline repeated measure-
ments, or the maximum follow-up time of the studies (Web
Table 5).
Changes in CVD risk classiﬁcation
Incorporating repeated measurements of SBP, total cho-
lesterol, and HDL cholesterol into the risk models improved
their sensitivity (for model 2 vs. model 1, event NRI= 1.54%
(95% CI: 0.84, 2.24), and for model 3 vs. model 1, event
NRI = 2.14% (95% CI: 1.48, 2.79); Table 3). Only model 2
signiﬁcantly improved speciﬁcity in comparison with model 1
(nonevent NRI = 2.15%, 95% CI: 1.97, 2.34; Table 3). The
overall net reclassiﬁcation of people according to 5-year CVD
risk category was improved in both model 2 and model 3,
with overall NRIs of 0.0369 (95% CI: 0.0303, 0.0436) and
0.0177 (95% CI: 0.0110, 0.0243), respectively. The overall
NRI was improved in model 2 compared with model 3
(P < 0.001), primarily due to greater speciﬁcity in model 2
compared with model 3 (P < 0.001). Model 3 showed greater
sensitivity thanmodel 2 (P= 0.007).
Of the 5,004 people who contributed data to the validation
data set and experienced a CVD event during the risk prediction
period, 46 extra people (0.9%) were correctly identiﬁed as being
at high risk under model 2 compared with model 1, while an
extra 62 people (1.2%) were identiﬁed under model 3 compared
withmodel 1 (WebTable 6). Of thosewho did not have an event
during the risk prediction period (n= 59,122), an extra 745 peo-
ple (1.3%) were reclassiﬁed as being at low risk under model 2
as compared with model 1. The results of the category-free NRI
Basic model
Basic model + systolic blood pressure
Basic model + total cholesterol
Basic model + HDL cholesterol
Model 1
Model 2
Model 3
0.6333 
0.6536 
0.6399 
0.6436
0.6687
0.6727 
0.6711 
0 0.02 0.04
Overall C-IndexVersus Basic ModelModel Versus Model 1
Change 95% CIChange 95% CI
0.0023, 0.0057
0.0005, 0.0042
0.6257, 0.6409
0.6461, 0.6610
0.6324, 0.6474
0.6361, 0.6511
0.6615, 6760
0.6655, 0.6799
0.6639, 0.6783
Change in C-Index
0.0104 
0.0355
0.0394 
0.0378
0.0067 0.0044, 0.0089
0.0086, 0.0121
0.0313, 0.0396
0.0353, 0.0436
0.0336, 0.0420
0.0203 0.0167, 0.0239
Change 95% CI
0 Referent
Referent
0.0040 
0.0023 
0
Figure 1. Change in cardiovascular disease (CVD) risk discrimination between the models in the validation data set in a study of CVD risk predic-
tion, Emerging Risk Factors Collaboration, 1962–2014. A total of 66,353 people from 38 studies contributed to the estimation of 5-year CVD risk
(i.e., contributed to the validation data and were alive at the time of CVD risk prediction). Of these, 2,667 people experienced a CVD event during
the 5-year CVD risk estimation period. Models were stratiﬁed by sex and adjusted, where appropriate, for baseline conventional CVD risk factors:
age, smoking status, history of diabetes, and baseline systolic blood pressure (SBP), total cholesterol, and high-density lipoprotein (HDL) choles-
terol. Point estimates on the right-hand side of the graph relate to the improvement in risk prediction. Model 1 included variables from the basic
model and baseline measures of SBP, total cholesterol, and HDL cholesterol. Model 2 included variables from the basic model and cumulative
mean values of previous measures of SBP, total cholesterol, and HDL cholesterol. Model 3 included variables from the basic model and summary
information from the longitudinal mixed-effects model of repeatedmeasurements of SBP, total cholesterol, and HDL cholesterol.
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were consistent; compared with model 1, the overall NRI was
0.4562 (95% CI: 0.4256, 0.4867) for model 2 and 0.0824 (95%
CI: 0.0583, 0.1065) formodel 3 (Table 3).
Sensitivity analyses
Changes in C-indices were similar when separate survival
models were ﬁtted for each study and stratiﬁed by sex (Web
Figure 7). The overall change in C-index (0.0014, 95% CI:
−0.0010, 0.0039) was slightly smaller than the change in
C-index in the main results when separate longitudinal mod-
els were ﬁtted for each study for model 3. When the analysis
was restricted to participants with 2 or more postbaseline
repeated measurements of SBP, the overall change in C-index
(relative to model 1) increased for both model 2 (0.0072, 95%
CI: 0.0030, 0.0115) and model 3 (0.0059, 95% CI: 0.0016,
0.0101), although the 95% conﬁdence intervals were wide
and overlapped with those observed in the main analysis.
However, less heterogeneity was observed (for model 2 com-
pared with model 1, I2 = 44% (P = 0.014), and for model 3
comparedwithmodel 1, I2= 39% (P= 0.032);Web Figure 8).
There was no evidence that the change in C-index varied
between younger (age 40–69 years) and older (age ≥70 years)
participants, although the available sample size was limited,
since only 22 of the 38 studies could be included (Web Figure 9
(parts A and B)). In the ﬁnal sensitivity analysis restricted to
studies with 10 years of follow-up and estimating 10-year
CVD risk, the changes in C-indices relative to model 1 were
0.0053 (95% CI: 0.0039, 0.0066) for model 2 and 0.0034
(95%CI: 0.0018, 0.0049) for model 3 (Web Figure 10).
DISCUSSION
The current analysis of 829,251 postbaseline repeated mea-
surements from 191,445 people across 38 cohorts reliably
assessed the added beneﬁt of incorporating repeated measure-
ments of blood pressure and cholesterol into CVD risk prediction
algorithms. Using cumulative mean values of repeated measure-
ments of these risk predictors improved discrimination by a
similar magnitude as when total cholesterol, a conventional
risk predictor, was added to a basic risk prediction model
including age, sex, smoking status, and history of diabetes.
Stratiﬁcation of patients according to risk is used to guide clin-
ical treatment decisions, and interpretation of the clinical ben-
eﬁt of adding a predictor to a risk model typically takes into
account both improvements in discrimination and risk reclas-
siﬁcation, as well as the cost of obtaining the risk factor data.
In our study, both methods for modeling repeated measure-
ments improved the sensitivity of themodel, and the cumulative-
means model produced slight gains in speciﬁcity compared with
the use of single measurements of risk predictors. The results of
our study suggest that an extra 0.9% and 1.2% of people would
have been correctly identiﬁed as being at high risk undermodels
2 and 3, respectively, and could be identiﬁed as potential targets
for treatment to reduce absolute risk levels if the models were
applied in practice. Overall improvements in reclassiﬁcation
were greater in model 2 than in model 3, driven by gains in
speciﬁcity. An extra 1.3% of people who did not experience
CVD events were correctly identiﬁed as being at low risk under
model 2, and thus adverse events related to unnecessary treat-
ment in those individuals could potentially be avoided. Further-
more, improvement in risk prediction performance may be
greater with the inclusion of more repeated measurements, as
evidenced by the results of our sensitivity analysis. Although
the 95% conﬁdence intervals were wide and overlapped with
those in the main analysis, there was some evidence of greater
improvement in C-index, particularly for the longitudinal model
(point estimates were 1.8 and 2.6 times those for models 2 and
3, respectively), when data were restricted to people with at least
2 postbaseline repeatedmeasurements of SBP.
Table 3. Change in Cardiovascular Disease Classiﬁcation Using RepeatedMeasurements of Systolic Blood
Pressure, Total Cholesterol, and High-Density Lipoprotein Cholesterol as Predictors in a Study of Cardiovascular
Disease Risk Prediction, Emerging Risk Factors Collaboration, 1962–2014
NRI Measure
andModela
NRI
Event
NRI 95%CI
Nonevent
NRI 95%CI
Overall
NRIb 95%CI
Categorical NRI
Model 1 0 Referent 0 Referent 0 Referent
Model 2 0.0154 0.0084, 0.0224 0.0215 0.0197, 0.0234 0.0369 0.0303, 0.0436
Model 3 0.0214 0.0148, 0.0279 −0.0037 −0.0058,−0.0016 0.0177 0.0110, 0.0243
Continuous NRI
Model 1 0 Referent 0 Referent 0 Referent
Model 2 0.0979 0.0686, 0.1272 0.3583 0.3521, 0.3645 0.4562 0.4256, 0.4867
Model 3 0.2234 0.2003, 0.2466 −0.1410 −0.1488, 0.1333 0.0824 0.0583, 0.1065
Abbreviations: CI, conﬁdence interval; HDL, high-density lipoprotein; NRI, net reclassiﬁcation improvement; SBP,
systolic blood pressure.
a Model 1: baseline measures of SBP, total cholesterol, and HDL cholesterol. Model 2: cumulative mean values of
previous measurements of SBP, total cholesterol, and HDL cholesterol. Model 3: longitudinal mixed-effects model of
repeatedmeasurements of SBP, total cholesterol, and HDL cholesterol.
b The overall NRI could range from−2 to+2.
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Two methods for modeling repeated data were compared:
ﬁrst, a simple cumulative-means approach, and second, a
more complex longitudinal modeling approach used to gener-
ate a time-independent usual risk predictor level and a slope
trajectory. Both methods offer the advantage of handling
within-person variability in risk factors, while the second also
allows for estimation of risk associations with slope trajecto-
ries. Thus, greater improvements in risk prediction ability will
be more likely for risk factors with greater within-person vari-
ation and more variable trajectories over time. The hazard
ratios for the intercepts of SBP and total cholesterol were
slightly stronger under the longitudinal model than under the
cumulative-means model, which likely reﬂects improvements
in accounting for measurement error. There was little gained
by adding slopes for these variables into our model. However,
given the relatively short time of approximately 2 years on
average between repeatedmeasurements, incorporating slopes
as well as intercepts from longitudinal modeling may result in
greater improvements in risk prediction when there are more
repeated measurements taken over a longer time period.
Our results support earlier ﬁndings by Paynter et al. (12),
who used regression calibration to estimate long-term “usual”
levels of SBP, total cholesterol, and HDL cholesterol as risk
predictors for coronary heart disease. Although their approach
showed no statistically signiﬁcant improvement in C-indices
compared with the use of single measurements of risk factors—
possibly due to the smaller sample size of 12,834 participants—
the changes in C-indices (0.003 for men and 0.005 for women)
were similar to those seen in the present study.
This was the ﬁrst study, to our knowledge, to quantify the
improvement in CVD risk prediction gained from using
repeated measurements of multiple risk predictors. The high
number of CVD events and the large sample size meant that
we could more precisely quantify improvements in predictive
ability, and the inclusion of participants from 17 countries en-
hances the reliability and generalizability of the results. In addi-
tion to these major strengths, our study had some limitations.
Firstly, in order to maximize the availability of repeated mea-
surements for the model derivation and the length of follow-up
in the validation data set, we estimated 5-year CVD risk rather
than the more commonly used 10-year CVD risk, although we
assessed 10-year CVD risk in the subset of studies with 10 or
more years of follow-up. Secondly, we restricted our investiga-
tion to incorporating repeated measurements of continuous con-
ventional risk factors, but in future research, investigators could
examine the use of repeated measurements of other biochemical
factors or conventional categorical risk factors, such as smoking
status. Thirdly, we were unable to adjust the results for changes
in medication use over time, as this was recorded in too few of
the included studies. However, we included only participants
without CVD at baseline. Hypertension was not well managed
at the timemany of the studies were conducted, and the trajecto-
ries of total and HDL cholesterol remained mostly stable over
time, suggesting that medication use was unlikely to have
affected the main results. Fourthly, there was considerable het-
erogeneity in the C-indices. This is probably explained in part
by the inclusion of participants without postbaseline measure-
ments in the main analysis; less heterogeneity was observed in
the sensitivity analysis restricted to participants with 2 or more
postbaseline measurements of SBP. Finally, the inclusion of
participants without postbaseline repeated measurements in
the main analysis also probably diluted the results. This was
evidenced in the sensitivity analysis restricted to participants
with 2 or more postbaseline measurements of SBP, which
showed some evidence of greater improvements in discrimi-
nation than were observed in the main analysis.
Our aim in this study was to compare 2 different methods of
utilizing already-available data from repeated measurements
of continuous conventional risk predictors, but this study does
not provide evidence on whether such extra measurements of
risk factors should be taken in practice or how frequently the
factors should be measured. Instead, the results of this study
suggest that, in principle, the inclusion of repeated risk factor
measurements in CVD risk prediction models improves pre-
diction accuracy and allows predictions to be updated over
time. The methods outlined in this paper may provide a useful
approach to utilizing available repeated-measures data, such as
those readily available in electronic health records, to achieve
small gains in risk prediction. Application of these methods to
existing data sets, such as primary care records that are more
complex than cohort data, and assessment of their clinical util-
ity and cost-effectiveness in these contexts is needed.
In conclusion, incorporating on average 1 postbaseline
repeat measurement of SBP, total cholesterol, and HDL cho-
lesterol into CVD risk prediction models can result in slight
improvements in risk discrimination and reclassiﬁcation.
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